The global head and neck cancer therapeutics market size is expected to reach USD 4.43 billion by 2030, according to a new report. The market is expected to grow at a CAGR of 11.8% from 2024 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market. ![Head And Neck Cancer Therapeutics Market]( "Head And Neck Cancer Therapeutics Market")
According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.
Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.
Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.
Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.
According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.
Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.
Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.
Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.
Head And Neck Cancer Therapeutics Market Report Highlights
- Immunotherapy led the market and accounted for 60.07% of the global revenue share in 2023 and is expected to grow at the fastest CAGR during the forecast period.
- Injectable led the market in 2023 and is expected to grow at a CAGR of 12.0% over the forecast period. Injectable medications play an important role in systemic therapies, delivering targeted agents to combat malignancy cells.
- Retail & specialty pharmacies led the market with a market share of 57.67% in 2023 and is expected to grow at the fastest CAR during the forecast period.
- The head and neck cancer therapeutics market in Asia Pacific is anticipated to witness the fastest growth in the market owing to the increasing prevalence of head & neck cancer, growing awareness about malignancy treatment, rising disposable income, and increasing healthcare reforms.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapy Type
1.2.2. Route of Administration
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Therapy Type
1.2.2. Route of Administration
1.2.3. Distribution Channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Therapy Type and Route of Administration Segment Snapshot
2.3 Distribution Channel Segment Snapshot
2.4 Competitive Landscape Snapshot
2.2 Therapy Type and Route of Administration Segment Snapshot
2.3 Distribution Channel Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Head and Neck Cancer Therapeutics Market Variables, Trends, and Scope
3.1 Head and Neck Cancer Therapeutics Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increase in Prevalence of Head and Neck Cancers
3.2.1.2 Rising Geriatric Population
3.2.1.3 Increasing R&D and Strong Presence of Pipeline Products
3.2.1.4 Supportive Reimbursement Policies & Rising Awareness About Disease
3.2.2 Market Restraint Analysis
3.2.2.1 Paucity of Data Related to Safety and Efficacy
3.2.2.2 High Cost of Treatment
3.3 Head and Neck Cancer Therapeutics Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Macroeconomic Analysis
3.4 Pipeline Analysis
3.4.1 Phase 3 Pipeline drugs under clinical trails
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increase in Prevalence of Head and Neck Cancers
3.2.1.2 Rising Geriatric Population
3.2.1.3 Increasing R&D and Strong Presence of Pipeline Products
3.2.1.4 Supportive Reimbursement Policies & Rising Awareness About Disease
3.2.2 Market Restraint Analysis
3.2.2.1 Paucity of Data Related to Safety and Efficacy
3.2.2.2 High Cost of Treatment
3.3 Head and Neck Cancer Therapeutics Market Analysis Tools
3.3.1 Porter’s Five Forces Analysis
3.3.2 Macroeconomic Analysis
3.4 Pipeline Analysis
3.4.1 Phase 3 Pipeline drugs under clinical trails
Chapter 4 Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis
4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
4.2 Therapy Type Movement Analysis & Market Share, 2023 & 2030
4.3 Chemotherapy
4.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
4.4 Immunotherapy
4.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
4.5 Targeted Therapy
4.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)
4.2 Therapy Type Movement Analysis & Market Share, 2023 & 2030
4.3 Chemotherapy
4.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
4.4 Immunotherapy
4.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
4.5 Targeted Therapy
4.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 5 Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis
5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
5.2 Route of Administration Movement Analysis & Market Share, 2023 & 2030
5.3 Injectable
5.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
5.4 Oral
5.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
5.2 Route of Administration Movement Analysis & Market Share, 2023 & 2030
5.3 Injectable
5.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
5.4 Oral
5.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 6 Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis
6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
6.2 Distribution Channel Movement Analysis & Market Share, 2023 & 2030
6.3 Retail & Specialty Pharmacies
6.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
6.4 Hospital Pharmacies
6.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
6.5 Online Pharmacies
6.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)
6.2 Distribution Channel Movement Analysis & Market Share, 2023 & 2030
6.3 Retail & Specialty Pharmacies
6.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
6.4 Hospital Pharmacies
6.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
6.5 Online Pharmacies
6.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)
Chapter 7 Head and Neck Cancer Therapeutics Market: Regional Estimates and Trend Analysis, by Therapy Type, by Route of Administration, by Distribution Channel
7.1 Head and Neck Cancer Therapeutics Market: Regional Outlook
7.2 North America
7.2.1 North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 Key Country Dynamics
7.2.2.2 U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2.3 Target Disease: Cancer Incidence
7.2.2.4 Market and Competitive Scenario
7.2.2.5 Regulatory Framework
7.2.2.6 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Key Country Dynamics
7.2.3.2 Canada Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3.3 Target Disease: Cancer Incidence
7.2.3.4 Market and Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2 UK
7.3.2.1 Key Country Dynamics
7.3.2.2 UK Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2.3 Target Disease Prevalence
7.3.2.4 Market and Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Key Country Dynamics
7.3.3.2 Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3.3 Target Disease Prevalence
7.3.3.4 Market and Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 Key Country Dynamics
7.3.4.2 France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4.3 Target Disease Prevalence
7.3.4.4 Market and Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Spain
7.3.5.1 Key Country Dynamics
7.3.5.2 Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5.3 Target Disease Prevalence
7.3.5.4 Market and Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Key Country Dynamics
7.3.6.2 Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6.3 Target Disease Prevalence
7.3.6.4 Market and Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Key Country Dynamics
7.3.7.2 Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7.3 Target Disease Prevalence
7.3.7.4 Market and Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Key Country Dynamics
7.3.8.2 Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8.3 Target Disease Prevalence
7.3.8.4 Market and Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Key Country Dynamics
7.3.9.2 Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9.3 Target Disease Prevalence
7.3.9.4 Market and Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.3.10 Rest of Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Key Country Dynamics
7.4.2.2 Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2.3 Target Disease Prevalence
7.4.2.4 Market and Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 Key Country Dynamics
7.4.3.2 China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3.3 Target Disease Prevalence
7.4.3.4 Market and Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 India
7.4.4.1 Key Country Dynamics
7.4.4.2 India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4.3 Target Disease Prevalence
7.4.4.4 Market and Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Key Country Dynamics
7.4.5.2 Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5.3 Target Disease Prevalence
7.4.5.4 Market and Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Key Country Dynamics
7.4.6.2 Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6.3 Target Disease Prevalence
7.4.6.4 Market and Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 South Korea
7.4.7.1 Key Country Dynamics
7.4.7.2 South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7.3 Target Disease Prevalence
7.4.7.4 Market and Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.4.8 Rest of Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Key Country Dynamics
7.5.2.2 Brazil Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2.3 Target Disease Prevalence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Key Country Dynamics
7.5.3.2 Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3.3 Target Disease: Cancer Incidence
7.5.3.4 Market and Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Key Country Dynamics
7.5.4.2 Argentina Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4.3 Target Disease Prevalence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.5.5 Rest of Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6 Middle East and Africa
7.6.1 MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 Key Country Dynamics
7.6.2.2 South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2.3 Target Disease Prevalence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Key Country Dynamics
7.6.3.2 Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.3.3 Target Disease Prevalence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 Key Country Dynamics
7.6.4.2 UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4.3 Target Disease Prevalence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Key Country Dynamics
7.6.5.2 Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5.3 Target Disease Prevalence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
7.6.6 Rest of MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2 North America
7.2.1 North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 Key Country Dynamics
7.2.2.2 U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2.3 Target Disease: Cancer Incidence
7.2.2.4 Market and Competitive Scenario
7.2.2.5 Regulatory Framework
7.2.2.6 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Key Country Dynamics
7.2.3.2 Canada Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3.3 Target Disease: Cancer Incidence
7.2.3.4 Market and Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2 UK
7.3.2.1 Key Country Dynamics
7.3.2.2 UK Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2.3 Target Disease Prevalence
7.3.2.4 Market and Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Key Country Dynamics
7.3.3.2 Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3.3 Target Disease Prevalence
7.3.3.4 Market and Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 Key Country Dynamics
7.3.4.2 France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4.3 Target Disease Prevalence
7.3.4.4 Market and Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Spain
7.3.5.1 Key Country Dynamics
7.3.5.2 Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5.3 Target Disease Prevalence
7.3.5.4 Market and Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Italy
7.3.6.1 Key Country Dynamics
7.3.6.2 Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6.3 Target Disease Prevalence
7.3.6.4 Market and Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Denmark
7.3.7.1 Key Country Dynamics
7.3.7.2 Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7.3 Target Disease Prevalence
7.3.7.4 Market and Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Sweden
7.3.8.1 Key Country Dynamics
7.3.8.2 Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8.3 Target Disease Prevalence
7.3.8.4 Market and Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Key Country Dynamics
7.3.9.2 Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9.3 Target Disease Prevalence
7.3.9.4 Market and Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.3.10 Rest of Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Key Country Dynamics
7.4.2.2 Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2.3 Target Disease Prevalence
7.4.2.4 Market and Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 Key Country Dynamics
7.4.3.2 China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3.3 Target Disease Prevalence
7.4.3.4 Market and Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 India
7.4.4.1 Key Country Dynamics
7.4.4.2 India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4.3 Target Disease Prevalence
7.4.4.4 Market and Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Key Country Dynamics
7.4.5.2 Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5.3 Target Disease Prevalence
7.4.5.4 Market and Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 Thailand
7.4.6.1 Key Country Dynamics
7.4.6.2 Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6.3 Target Disease Prevalence
7.4.6.4 Market and Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 South Korea
7.4.7.1 Key Country Dynamics
7.4.7.2 South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7.3 Target Disease Prevalence
7.4.7.4 Market and Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.4.8 Rest of Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Key Country Dynamics
7.5.2.2 Brazil Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2.3 Target Disease Prevalence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Mexico
7.5.3.1 Key Country Dynamics
7.5.3.2 Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3.3 Target Disease: Cancer Incidence
7.5.3.4 Market and Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Key Country Dynamics
7.5.4.2 Argentina Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.4.3 Target Disease Prevalence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.5.5 Rest of Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6 Middle East and Africa
7.6.1 MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 Key Country Dynamics
7.6.2.2 South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2.3 Target Disease Prevalence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Key Country Dynamics
7.6.3.2 Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6.3.3 Target Disease Prevalence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 Key Country Dynamics
7.6.4.2 UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4.3 Target Disease Prevalence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Key Country Dynamics
7.6.5.2 Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5.3 Target Disease Prevalence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
7.6.6 Rest of MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Recent Developments & Impact Analysis, By Key Market Participants
8.2 Company Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Eli Lilly and Company
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Sanofi
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.6. Merck & Co., Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.7. Cumberland Pharmaceuticals, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.8. Bristol-Myers Squibb Company (BMS)
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.9. AstraZeneca
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.10. Takeda Pharmaceutical Company Limited
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.11. Teva Pharmaceutical Industries Ltd.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.12. F. Hoffmann-La Roche Ltd
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.2 Company Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Eli Lilly and Company
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Sanofi
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.6. Merck & Co., Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.7. Cumberland Pharmaceuticals, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.8. Bristol-Myers Squibb Company (BMS)
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.9. AstraZeneca
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.10. Takeda Pharmaceutical Company Limited
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.11. Teva Pharmaceutical Industries Ltd.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.12. F. Hoffmann-La Roche Ltd
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
Table 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 22 UK Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 23 UK Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 24 UK Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 51 Australia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 2 List of Abbreviations
Table 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
Table 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 22 UK Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 23 UK Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 24 UK Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 51 Australia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
Table 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Head And neck cancer therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Therapy type and route of administration segment snapshot
Fig. 11 Distribution channel segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Head and neck cancer therapeutics market: Therapy type outlook & key takeaways
Fig. 17 Head and neck cancer therapeutics market: Therapy type movement analysis
Fig. 18 Global chemotherapy market, 2018 - 2030 (USD Million)
Fig. 19 Global immunotherapy market, 2018 - 2030 (USD Million)
Fig. 20 Global targeted therapy market, 2018 - 2030 (USD Million)
Fig. 21 Head and neck cancer therapeutics market: Route of administration outlook & key takeaways
Fig. 22 Head and neck cancer therapeutics market: Route of administration movement analysis
Fig. 23 Global injectable market, 2018 - 2030 (USD Million)
Fig. 24 Global oral market, 2018 - 2030 (USD Million)
Fig. 25 Head and neck cancer therapeutics market: Distribution channel outlook & key takeaways
Fig. 26 Head and neck cancer therapeutics market: Distribution channel movement analysis
Fig. 27 Global retail & specialty pharmacies market, 2018 - 2030 (USD Million)
Fig. 28 Global hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 29 Global online pharmacies market, 2018 - 2030 (USD Million)
Fig. 30 Head and neck cancer therapeutics market revenue, by region, 2023 & 2030 (USD Million)
Fig. 31 Regional marketplace: Key takeaways
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 North America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Key country dynamics
Fig. 35 U.S. head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 37 Key country dynamics
Fig. 38 Canada head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Canada: oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 40 Key country dynamics
Fig. 41 Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 UK head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 45 Key country dynamics
Fig. 46 Germany head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Oropharynx cancer incidence, 2020 - 2030
Fig. 48 Germany insurance coverage
Fig. 49 Key country dynamics
Fig. 50 France head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 52 Key country dynamics
Fig. 53 Spain head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 55 Key country dynamics
Fig. 56 Italy head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Larynx cancer incidence, 2020 - 2030
Fig. 58 Key country dynamics
Fig. 59 Denmark head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Oropharynx Cancer Incidence, 2020 - 2030
Fig. 61 Key country dynamics
Fig. 62 Sweden head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 64 Key country dynamics
Fig. 65 Norway head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 67 Rest of Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Japan head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Japan pharmaceutical registration
Fig. 72 Key country dynamics
Fig. 73 China head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Nasopharynx cancer incidence, 2020 - 2030
Fig. 75 Regulatory details: China
Fig. 76 Exclusivity formula
Fig. 77 Key country dynamics
Fig. 78 India head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 80 Registration details: India
Fig. 81 Key country dynamics
Fig. 82 Australia head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Lip, Oral Cavity Cancer incidence, 2020 to 2030
Fig. 84 Drug pricing: Australia
Fig. 85 Contribution of PBS by disease
Fig. 86 Key country dynamics
Fig. 87 Thailand head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Nasopharynx Cancer incidence, 2020 to 2030
Fig. 89 Key country dynamics
Fig. 90 South Korea head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Lip, Oral Cavity Cancer incidence 2020 to 2030
Fig. 92 Reimbursement scenario: South Korea
Fig. 93 Rest of Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Brazil head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Larynx Cancer Incidence, 2020 to 2030
Fig. 98 Regulatory framework
Fig. 99 Reimbursement scenario
Fig. 100 Key country dynamics
Fig. 101 Mexico head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 Mexico: oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 103 Argentina head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 104 Larynx cancer incidence, 2020 to 2030
Fig. 105 Argentina pharmaceuticals registration details
Fig. 106 Argentina pharmaceuticals reimbursement details
Fig. 107 Rest of Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 109 Key country dynamics
Fig. 110 South Africa head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 111 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 112 Regulatory framework: South Africa
Fig. 113 Regulatory framework: South Africa drug registration fees
Fig. 114 Key country dynamics
Fig. 115 Saudi Arabia head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 116 Nasopharynx cancer incidence, 2020 to 2030
Fig. 117 Key country dynamics
Fig. 118 UAE head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 119 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 120 Key country dynamics
Fig. 121 Kuwait head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 122 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 123 Regulatory framework: Kuwait
Fig. 124 Rest of MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 125 Key company categorization
Fig. 126 Company market share analysis, 2023
Fig. 127 Strategic framework
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Therapy type and route of administration segment snapshot
Fig. 11 Distribution channel segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Head and neck cancer therapeutics market: Therapy type outlook & key takeaways
Fig. 17 Head and neck cancer therapeutics market: Therapy type movement analysis
Fig. 18 Global chemotherapy market, 2018 - 2030 (USD Million)
Fig. 19 Global immunotherapy market, 2018 - 2030 (USD Million)
Fig. 20 Global targeted therapy market, 2018 - 2030 (USD Million)
Fig. 21 Head and neck cancer therapeutics market: Route of administration outlook & key takeaways
Fig. 22 Head and neck cancer therapeutics market: Route of administration movement analysis
Fig. 23 Global injectable market, 2018 - 2030 (USD Million)
Fig. 24 Global oral market, 2018 - 2030 (USD Million)
Fig. 25 Head and neck cancer therapeutics market: Distribution channel outlook & key takeaways
Fig. 26 Head and neck cancer therapeutics market: Distribution channel movement analysis
Fig. 27 Global retail & specialty pharmacies market, 2018 - 2030 (USD Million)
Fig. 28 Global hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 29 Global online pharmacies market, 2018 - 2030 (USD Million)
Fig. 30 Head and neck cancer therapeutics market revenue, by region, 2023 & 2030 (USD Million)
Fig. 31 Regional marketplace: Key takeaways
Fig. 32 Regional marketplace: Key takeaways
Fig. 33 North America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Key country dynamics
Fig. 35 U.S. head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 37 Key country dynamics
Fig. 38 Canada head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Canada: oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 40 Key country dynamics
Fig. 41 Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 UK head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 45 Key country dynamics
Fig. 46 Germany head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Oropharynx cancer incidence, 2020 - 2030
Fig. 48 Germany insurance coverage
Fig. 49 Key country dynamics
Fig. 50 France head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 52 Key country dynamics
Fig. 53 Spain head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 55 Key country dynamics
Fig. 56 Italy head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Larynx cancer incidence, 2020 - 2030
Fig. 58 Key country dynamics
Fig. 59 Denmark head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Oropharynx Cancer Incidence, 2020 - 2030
Fig. 61 Key country dynamics
Fig. 62 Sweden head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 64 Key country dynamics
Fig. 65 Norway head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 67 Rest of Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Japan head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Japan pharmaceutical registration
Fig. 72 Key country dynamics
Fig. 73 China head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Nasopharynx cancer incidence, 2020 - 2030
Fig. 75 Regulatory details: China
Fig. 76 Exclusivity formula
Fig. 77 Key country dynamics
Fig. 78 India head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 80 Registration details: India
Fig. 81 Key country dynamics
Fig. 82 Australia head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Lip, Oral Cavity Cancer incidence, 2020 to 2030
Fig. 84 Drug pricing: Australia
Fig. 85 Contribution of PBS by disease
Fig. 86 Key country dynamics
Fig. 87 Thailand head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Nasopharynx Cancer incidence, 2020 to 2030
Fig. 89 Key country dynamics
Fig. 90 South Korea head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Lip, Oral Cavity Cancer incidence 2020 to 2030
Fig. 92 Reimbursement scenario: South Korea
Fig. 93 Rest of Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 Brazil head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Larynx Cancer Incidence, 2020 to 2030
Fig. 98 Regulatory framework
Fig. 99 Reimbursement scenario
Fig. 100 Key country dynamics
Fig. 101 Mexico head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 Mexico: oropharynx cancer: Estimated number of new cases, 2020 - 2040
Fig. 103 Argentina head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 104 Larynx cancer incidence, 2020 to 2030
Fig. 105 Argentina pharmaceuticals registration details
Fig. 106 Argentina pharmaceuticals reimbursement details
Fig. 107 Rest of Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 109 Key country dynamics
Fig. 110 South Africa head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 111 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 112 Regulatory framework: South Africa
Fig. 113 Regulatory framework: South Africa drug registration fees
Fig. 114 Key country dynamics
Fig. 115 Saudi Arabia head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 116 Nasopharynx cancer incidence, 2020 to 2030
Fig. 117 Key country dynamics
Fig. 118 UAE head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 119 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 120 Key country dynamics
Fig. 121 Kuwait head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 122 Lip, oral cavity cancer incidence, 2020 - 2030
Fig. 123 Regulatory framework: Kuwait
Fig. 124 Rest of MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 125 Key company categorization
Fig. 126 Company market share analysis, 2023
Fig. 127 Strategic framework
Companies Mentioned
- Eli Lilly and Company
- Sanofi
- Merck & Co., Inc.
- Cumberland Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company (BMS)
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.04 Billion |
| Forecasted Market Value ( USD | $ 4.43 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
